<contract>
    <parties>
        <party>
            <name>Alkermes, Inc.</name>
            <type>Corporation</type>
            <capacity>Wholly owned indirect subsidiary of Alkermes plc</capacity>
            <address>900 Winter Street, Waltham, Massachusetts 02451</address>
        </party>
        <party>
            <name>Mural Oncology, Inc.</name>
            <type>Corporation</type>
            <capacity>Wholly owned direct subsidiary of Mural Oncology plc</capacity>
            <address>852 Winter Street, Waltham, Massachusetts 02451</address>
        </party>
    </parties>
    <offerAndAcceptance>
        <offer>Transition services to be provided from Alkermes US to Mural US.</offer>
        <acceptance>Mural US accepts the offer for services as detailed in the Agreement.</acceptance>
        <meetingOfMinds>Agreement signed by both parties on November 13, 2023.</meetingOfMinds>
    </offerAndAcceptance>
    <consideration>
        <description>Provision of transition services.</description>
        <value>To be determined based on Transition Service Schedules.</value>
    </consideration>
    <intentionToCreateLegalRelations>Both parties intend to create legal relations through this Agreement.</intentionToCreateLegalRelations>
    <legalityOfPurpose>The purpose of this contract is legal and valid.</legalityOfPurpose>
    <certaintyOfTerms>
        <subjectMatter>Provision of specified services during the term of the Agreement.</subjectMatter>
        <price>Fees set forth in Transition Service Schedule.</price>
        <timeForPerformance>Service period extends to a maximum of two years.</timeForPerformance>
    </certaintyOfTerms>
    <consent>Consent required for subcontracting and third-party agreements as specified.</consent>
    <formAndFormalities>Agreement executed in counterparts and electronically.</formAndFormalities>
    <durationAndTermination>
        <duration>Term of services not to exceed two years following the commencement.</duration>
        <terminationConditions>Termination upon breach or insolvency as specified.</terminationConditions>
        <renewalTerms>Renewal terms subject to mutual agreement.</renewalTerms>
    </durationAndTermination>
    <representationsAndWarranties>Parties acknowledge provisions regarding indemnification and liability.</representationsAndWarranties>
    <indemnification>Indemnification terms specified in Article VIII of the Agreement.</indemnification>
    <disputeResolution>
        <method>Negotiation followed by arbitration.</method>
        <details>Details provided in Article VII of the Agreement.</details>
    </disputeResolution>
    <governingLawAndJurisdiction>
        <governingLaw>State of Delaware</governingLaw>
        <jurisdiction>Delaware Court of Chancery</jurisdiction>
    </governingLawAndJurisdiction>
    <severability>If any provision is invalid, the remaining provisions shall remain effective.</severability>
    <forceMajeure>Neither party liable for delays due to unforeseen circumstances.</forceMajeure>
    <confidentiality>Obligations of confidentiality and data protection in Article IX.</confidentiality>
    <assignmentAndDelegation>Assignment subject to consent; not unreasonably withheld.</assignmentAndDelegation>
    <signatures>
        <signature>
            <partyName>Alkermes, Inc.</partyName>
            <dateSigned>2023-11-13</dateSigned>
            <declaration>Executed by Iain Brown, SVP, Chief Financial Officer</declaration>
        </signature>
        <signature>
            <partyName>Mural Oncology, Inc.</partyName>
            <dateSigned>2023-11-13</dateSigned>
            <declaration>Executed by Caroline Loew, Ph.D., President</declaration>
        </signature>
    </signatures>
</contract>